Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes. Nucleic acid drugs are being developed as novel therapeutic modalities. They have great potential to treat human diseases such as cancers, viral infections, and genetic disorders due to unique characteristics that make it possible to approach undruggable targets using classical small molecule or protein/antibody-based biologics. Currently, mRNA vaccines, small interfering RNA (siRNA, small interfering RNA) and antisense nucleic acids (ASO, antisense oligodeoxyncleotides) are the main forms of nucleic acid drug development in clinical practice.
麻豆原创 Analysis and Insights: Global Nucleic Acid Drugs 麻豆原创
The global Nucleic Acid Drugs market is projected to grow from US$ 12490 million in 2024 to US$ 15540 million by 2030, at a Compound Annual Growth Rate (CAGR) of 3.7% during the forecast period.
The global key companies of Nucleic Acid Drugs include Pfizer, ModeBiogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Alnylam, Pfizer, etc. These global top five players had a share approximately 98% in terms of revenue. Based on the product type, the Nucleic Acid Drugs is primarily split into Antisense Oligonucleotides (ASOs) Drugs, Small Interfering RNA (siRNA) Drugs, etc.Based on the Nucleic Acid Drugs application, the Nucleic Acid Drugs market is sub-segmented into several major Application, like Neuromuscular Diseases, hATTR, Others, etc.
Report Covers:
This report presents an overview of global market for Nucleic Acid Drugs market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Nucleic Acid Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Nucleic Acid Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Nucleic Acid Drugs revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Nucleic Acid Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Nucleic Acid Drugs revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
Segment by Type
Antisense Oligonucleotides (ASO)
siRNA
mRNA
Segment by Application
Neuromuscular Diseases
hATTR
COVID-19
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Nucleic Acid Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nucleic Acid Drugs companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nucleic Acid Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Nucleic Acid Drugs 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Antisense Oligonucleotides (ASO)
1.2.3 siRNA
1.2.4 mRNA
1.3 麻豆原创 by Application
1.3.1 Global Nucleic Acid Drugs 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Neuromuscular Diseases
1.3.3 hATTR
1.3.4 COVID-19
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nucleic Acid Drugs 麻豆原创 Perspective (2019-2030)
2.2 Global Nucleic Acid Drugs Growth Trends by Region
2.2.1 Nucleic Acid Drugs 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Nucleic Acid Drugs Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Nucleic Acid Drugs Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Nucleic Acid Drugs 麻豆原创 Dynamics
2.3.1 Nucleic Acid Drugs Industry Trends
2.3.2 Nucleic Acid Drugs 麻豆原创 Drivers
2.3.3 Nucleic Acid Drugs 麻豆原创 Challenges
2.3.4 Nucleic Acid Drugs 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Nucleic Acid Drugs by Players
3.1.1 Global Nucleic Acid Drugs Revenue by Players (2019-2024)
3.1.2 Global Nucleic Acid Drugs Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Nucleic Acid Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Nucleic Acid Drugs, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Nucleic Acid Drugs 麻豆原创 Concentration Ratio
3.4.1 Global Nucleic Acid Drugs 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid Drugs Revenue in 2023
3.5 Global Key Players of Nucleic Acid Drugs Head office and Area Served
3.6 Global Key Players of Nucleic Acid Drugs, Product and Application
3.7 Global Key Players of Nucleic Acid Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Nucleic Acid Drugs Breakdown Data by Type
4.1 Global Nucleic Acid Drugs Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Nucleic Acid Drugs Forecasted 麻豆原创 Size by Type (2025-2030)
5 Nucleic Acid Drugs Breakdown Data by Application
5.1 Global Nucleic Acid Drugs Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Nucleic Acid Drugs Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Nucleic Acid Drugs 麻豆原创 Size (2019-2030)
6.2 North America Nucleic Acid Drugs 麻豆原创 Size by Type
6.2.1 North America Nucleic Acid Drugs 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Nucleic Acid Drugs 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Nucleic Acid Drugs 麻豆原创 Share by Type (2019-2030)
6.3 North America Nucleic Acid Drugs 麻豆原创 Size by Application
6.3.1 North America Nucleic Acid Drugs 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Nucleic Acid Drugs 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Nucleic Acid Drugs 麻豆原创 Share by Application (2019-2030)
6.4 North America Nucleic Acid Drugs 麻豆原创 Size by Country
6.4.1 North America Nucleic Acid Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Nucleic Acid Drugs 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Nucleic Acid Drugs 麻豆原创 Size by Country (2025-2030)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Nucleic Acid Drugs 麻豆原创 Size (2019-2030)
7.2 Europe Nucleic Acid Drugs 麻豆原创 Size by Type
7.2.1 Europe Nucleic Acid Drugs 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Nucleic Acid Drugs 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Nucleic Acid Drugs 麻豆原创 Share by Type (2019-2030)
7.3 Europe Nucleic Acid Drugs 麻豆原创 Size by Application
7.3.1 Europe Nucleic Acid Drugs 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Nucleic Acid Drugs 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Nucleic Acid Drugs 麻豆原创 Share by Application (2019-2030)
7.4 Europe Nucleic Acid Drugs 麻豆原创 Size by Country
7.4.1 Europe Nucleic Acid Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Nucleic Acid Drugs 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Nucleic Acid Drugs 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Nucleic Acid Drugs 麻豆原创 Size (2019-2030)
8.2 China Nucleic Acid Drugs 麻豆原创 Size by Type
8.2.1 China Nucleic Acid Drugs 麻豆原创 Size by Type (2019-2024)
8.2.2 China Nucleic Acid Drugs 麻豆原创 Size by Type (2025-2030)
8.2.3 China Nucleic Acid Drugs 麻豆原创 Share by Type (2019-2030)
8.3 China Nucleic Acid Drugs 麻豆原创 Size by Application
8.3.1 China Nucleic Acid Drugs 麻豆原创 Size by Application (2019-2024)
8.3.2 China Nucleic Acid Drugs 麻豆原创 Size by Application (2025-2030)
8.3.3 China Nucleic Acid Drugs 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Nucleic Acid Drugs 麻豆原创 Size (2019-2030)
9.2 Asia Nucleic Acid Drugs 麻豆原创 Size by Type
9.2.1 Asia Nucleic Acid Drugs 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Nucleic Acid Drugs 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Nucleic Acid Drugs 麻豆原创 Share by Type (2019-2030)
9.3 Asia Nucleic Acid Drugs 麻豆原创 Size by Application
9.3.1 Asia Nucleic Acid Drugs 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Nucleic Acid Drugs 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Nucleic Acid Drugs 麻豆原创 Share by Application (2019-2030)
9.4 Asia Nucleic Acid Drugs 麻豆原创 Size by Region
9.4.1 Asia Nucleic Acid Drugs 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Nucleic Acid Drugs 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Nucleic Acid Drugs 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Nucleic Acid Drugs 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Nucleic Acid Drugs 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Nucleic Acid Drugs 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Nucleic Acid Drugs 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Nucleic Acid Drugs 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Nucleic Acid Drugs 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Nucleic Acid Drugs 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Nucleic Acid Drugs 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Nucleic Acid Drugs 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Nucleic Acid Drugs 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Nucleic Acid Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Nucleic Acid Drugs 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Nucleic Acid Drugs 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Details
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Nucleic Acid Drugs Introduction
11.1.4 Sarepta Therapeutics Revenue in Nucleic Acid Drugs Business (2019-2024)
11.1.5 Sarepta Therapeutics Recent Developments
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Details
11.2.2 Ionis Pharmaceuticals Business Overview
11.2.3 Ionis Pharmaceuticals Nucleic Acid Drugs Introduction
11.2.4 Ionis Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2019-2024)
11.2.5 Ionis Pharmaceuticals Recent Developments
11.3 Alnylam
11.3.1 Alnylam Company Details
11.3.2 Alnylam Business Overview
11.3.3 Alnylam Nucleic Acid Drugs Introduction
11.3.4 Alnylam Revenue in Nucleic Acid Drugs Business (2019-2024)
11.3.5 Alnylam Recent Developments
11.4 Biogen
11.4.1 Biogen Company Details
11.4.2 Biogen Business Overview
11.4.3 Biogen Nucleic Acid Drugs Introduction
11.4.4 Biogen Revenue in Nucleic Acid Drugs Business (2019-2024)
11.4.5 Biogen Recent Developments
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Details
11.5.2 Nippon Shinyaku Business Overview
11.5.3 Nippon Shinyaku Nucleic Acid Drugs Introduction
11.5.4 Nippon Shinyaku Revenue in Nucleic Acid Drugs Business (2019-2024)
11.5.5 Nippon Shinyaku Recent Developments
11.6 Sobi
11.6.1 Sobi Company Details
11.6.2 Sobi Business Overview
11.6.3 Sobi Nucleic Acid Drugs Introduction
11.6.4 Sobi Revenue in Nucleic Acid Drugs Business (2019-2024)
11.6.5 Sobi Recent Developments
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Nucleic Acid Drugs Introduction
11.7.4 Novartis Revenue in Nucleic Acid Drugs Business (2019-2024)
11.7.5 Novartis Recent Developments
11.8 BioNTech
11.8.1 BioNTech Company Details
11.8.2 BioNTech Business Overview
11.8.3 BioNTech Nucleic Acid Drugs Introduction
11.8.4 BioNTech Revenue in Nucleic Acid Drugs Business (2019-2024)
11.8.5 BioNTech Recent Developments
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Nucleic Acid Drugs Introduction
11.9.4 Pfizer Revenue in Nucleic Acid Drugs Business (2019-2024)
11.9.5 Pfizer Recent Developments
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Details
11.10.2 Moderna Therapeutics Business Overview
11.10.3 Moderna Therapeutics Nucleic Acid Drugs Introduction
11.10.4 Moderna Therapeutics Revenue in Nucleic Acid Drugs Business (2019-2024)
11.10.5 Moderna Therapeutics Recent Developments
11.11 Jazz Pharmaceuticals
11.11.1 Jazz Pharmaceuticals Company Details
11.11.2 Jazz Pharmaceuticals Business Overview
11.11.3 Jazz Pharmaceuticals Nucleic Acid Drugs Introduction
11.11.4 Jazz Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2019-2024)
11.11.5 Jazz Pharmaceuticals Recent Developments
11.12 CureVac
11.12.1 CureVac Company Details
11.12.2 CureVac Business Overview
11.12.3 CureVac Nucleic Acid Drugs Introduction
11.12.4 CureVac Revenue in Nucleic Acid Drugs Business (2019-2024)
11.12.5 CureVac Recent Developments
11.13 Regulus Therapeutics
11.13.1 Regulus Therapeutics Company Details
11.13.2 Regulus Therapeutics Business Overview
11.13.3 Regulus Therapeutics Nucleic Acid Drugs Introduction
11.13.4 Regulus Therapeutics Revenue in Nucleic Acid Drugs Business (2019-2024)
11.13.5 Regulus Therapeutics Recent Developments
11.14 ProQR
11.14.1 ProQR Company Details
11.14.2 ProQR Business Overview
11.14.3 ProQR Nucleic Acid Drugs Introduction
11.14.4 ProQR Revenue in Nucleic Acid Drugs Business (2019-2024)
11.14.5 ProQR Recent Developments
11.15 Secarna
11.15.1 Secarna Company Details
11.15.2 Secarna Business Overview
11.15.3 Secarna Nucleic Acid Drugs Introduction
11.15.4 Secarna Revenue in Nucleic Acid Drugs Business (2019-2024)
11.15.5 Secarna Recent Developments
11.16 MiNA Therapeutics
11.16.1 MiNA Therapeutics Company Details
11.16.2 MiNA Therapeutics Business Overview
11.16.3 MiNA Therapeutics Nucleic Acid Drugs Introduction
11.16.4 MiNA Therapeutics Revenue in Nucleic Acid Drugs Business (2019-2024)
11.16.5 MiNA Therapeutics Recent Developments
11.17 Sylentis
11.17.1 Sylentis Company Details
11.17.2 Sylentis Business Overview
11.17.3 Sylentis Nucleic Acid Drugs Introduction
11.17.4 Sylentis Revenue in Nucleic Acid Drugs Business (2019-2024)
11.17.5 Sylentis Recent Developments
11.18 Arrowhead
11.18.1 Arrowhead Company Details
11.18.2 Arrowhead Business Overview
11.18.3 Arrowhead Nucleic Acid Drugs Introduction
11.18.4 Arrowhead Revenue in Nucleic Acid Drugs Business (2019-2024)
11.18.5 Arrowhead Recent Developments
11.19 Silence Therapeutics
11.19.1 Silence Therapeutics Company Details
11.19.2 Silence Therapeutics Business Overview
11.19.3 Silence Therapeutics Nucleic Acid Drugs Introduction
11.19.4 Silence Therapeutics Revenue in Nucleic Acid Drugs Business (2019-2024)
11.19.5 Silence Therapeutics Recent Developments
11.20 Dicerna
11.20.1 Dicerna Company Details
11.20.2 Dicerna Business Overview
11.20.3 Dicerna Nucleic Acid Drugs Introduction
11.20.4 Dicerna Revenue in Nucleic Acid Drugs Business (2019-2024)
11.20.5 Dicerna Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
听
听
*If Applicable.